If you have been reading about Lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
=== Contraindications === Both rosiglitazone and pioglitazone are contraindicated in people with NYHA Class III and IV heart failure. They are not recommended for use in heart failure. In Europe, rosiglitazone was contraindicated for heart failure or history of heart failure with regard to all NYHA stages, for combined use with insulin and for acute coronary syndrome. The European Medicines Agency recommended on 23 September 2010 that Avandia be suspended from the European market.
Shōyu is officially divided into five main types by the JAS (Japanese Agricultural Standard) depending on differences in their ingredients and method of production. These types are koikuchi, usukuchi, tamari, saishikomi, and shiro. Most, but not all, Japanese soy sauces include wheat as a primary ingredient, which tends to give them a slightly sweeter taste than their Chinese counterparts. They also tend towards an alcoholic sherry-like flavor, sometimes enhanced by the addition of small amounts of alcohol as a natural preservative. The widely varying flavors of these soy sauces are not always interchangeable, so some recipes only call for one type or the other, much as a white wine cannot replace a red's flavor or beef stock does not make the same results as chicken stock. Some soy sauces made in the Japanese way or styled after them contain about 50% wheat.
Stock in the family's oil companies had been a major part of the foundation's assets, beginning with Standard Oil and later with its corporate descendants, including ExxonMobil. In December 2020, the foundation pledged to dump their fossil fuel holdings. With a $5 billion endowment, the Rockefeller Foundation was "the largest US foundation to embrace the rapidly growing divestment movement." CNN writer Matt Egan noted, "This divestment is especially symbolic because the Rockefeller Foundation was founded by oil money."
=== Limitations === The UK Government's Department of Health compiled a factsheet in 2014, in which it is stated that the key limitations to well-being, quality of life and life satisfaction research are that:
Sources: en.wikipedia.org
Other reported effects included feeling lazy, diuretic effects, no appetite loss, decongestant effects, stomach discomfort, and chills. Compared to LSD, ETH-LAD was described as lacking the push and sparkle of LSD, allowing for extraordinary experiences with none of LSD's demands, being less aggressive than LSD and lacking its "taking control" nature, having a greatly modified degree of visual distortion relative to LSD, having visual effects similar to LSD but much more gentle, and being more allowing than demanding. Informal online anecdotal reports have described ETH-LAD as highly visual, introspective, and sometimes more "analytical" or "neutral" than LSD, but have also reported heavier body load and stronger physical side effects such as nausea and discomfort especially at high doses. Other reported effects have included positive after-effects like increased creativity and well-being as well as adverse reactions such as confusion, emotional distress, and rarely severe agitation and paranoia.
Bismuth (83Bi) has 41 known isotopes, ranging from 184Bi to 224Bi. Bismuth has one nearly stable isotope but no stable isotopes, the standard atomic weight can be given from that isotope, bismuth-209. Though it is now known to be radioactive, it may still be considered practically stable because it has a half-life of 2.01×1019 years, which is more than a billion times the age of the universe. As a result, it is the longest lived known alpha emitter. Bismuth-209 is also the heaviest nearly stable isotope, with the longest lived isotope with a greater atomic weight being thorium-232. Besides 209Bi, the most stable bismuth radioisotopes are 210mBi with a half-life of 3.04 million years, 208Bi with a half-life of 368,000 years and 207Bi, with a half-life of 31.22 years, none of which occur in nature. All other isotopes have half-lives under 15 days, most under two hours. Of naturally occurring radioisotopes, the most stable is radiogenic 210Bi with a half-life of 5.012 days. 210mBi is unusual for being a nuclear isomer with a half-life many orders of magnitude longer than that of the ground state.
Sitagliptin was approved by the US Food and Drug Administration (FDA) in October 2006, and is sold under the brand name Januvia. In April 2007, the FDA approved an oral combination of sitagliptin/metformin sold under the brand name Janumet. In October 2011, the FDA approved an oral combination of sitagliptin/simvastatin sold under the brand name Juvisync. The extended release version of sitagliptin/metformin was approved in February 2012.
Sources: en.wikipedia.org
=== Quality of life === Several studies, primarily involving patients with GH deficiency, have suggested a crucial role of GH in both mental and emotional well-being and maintaining a high energy level. Adults with GH deficiency often have higher rates of depression than those without. While GH replacement therapy has been proposed to treat depression as a result of GH deficiency, the long-term effects of such therapy are unknown.
== Efficacy == There is no clear measure of the effectiveness of the war on drugs, and it has been widely called a policy failure. Thirty years into the campaign, a National Research Council report, "Informing America's Policy on Illegal Drugs" (2001), found that "existing drug-use monitoring systems are strikingly inadequate to support the full range of policy decisions that the nation must make." The report noted that studies of efforts to address drug usage and smuggling, from US military operations to eradicate coca fields in Colombia, to domestic drug treatment centers, had all been inconclusive, if the programs had been evaluated at all: It concluded, "It is unconscionable for this country to continue to carry out a public policy of this magnitude and cost without any way of knowing whether and to what extent it is having the desired effect." Writing in the New Statesmen in 2021, journalist James Bloodworth stated, "The war on drugs is a failure. We know this. We've long known it. In fact, there is such an abundance of evidence for its failure that we have more certainty here than in most areas of policy. ... According to the International Drug Policy Consortium there was a 31 per cent global increase in drug taking between 2011 and 2016. ...
== References == Berk, A A. LISP: the Language of Artificial Intelligence. New York: Van Nostrand Reinhold Company, 1985. 1-25. Lederberg, Joshua. An Instrumentation Crisis in Biology. Stanford University Medical School. Palo Alto, 1963. Lederberg, Joshua. Dendral-64 - a system for computer construction, enumeration and notation of organic molecules as tree structures and cyclic graphs. part i- notational algorithm for tree structures. Interim Report to the National Aeronautics and Space Administration, 15 December, 1964. Lederberg, Joshua. How Dendral Was Conceived and Born. ACM Symposium on the History of Medical Informatics, 5 November 1987, Rockefeller University. New York: National Library of Medicine, 1987. Alternate link to article Lindsay, Robert K., Bruce G. Buchanan, Edward A. Feigenbaum, and Joshua Lederberg. Applications of Artificial Intelligence for Organic Chemistry: The Dendral Project[link removed]. McGraw-Hill Book Company, 1980. Lindsay, Robert K., Bruce G. Buchanan, E. A. Feigenbaum, and Joshua Lederberg. DENDRAL: A Case Study of the First Expert System for Scientific Hypothesis Formation. Artificial Intelligence 61, 2 (1993): 209-261. November, Joseph A. “Digitizing Life: The Introduction of Computers to Biology and Medicine.” Doctoral dissertation, Princeton University, 2006 "Mit smarter Software zur Analytik 4.0." CHEManager (GIT Verlag). Accessed 15 October 2025. "Limitationen von Datenbanken und Möglichkeiten für künstliche Intelligenz." Wiley Analytical Science. Accessed 15 October 2025.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.